PENTRACOR GMBH - HEALTH FOR THE PORTFOLIO
Pentracor GmbH, a spin-off from the university environment, has been in operation since 2010. With its solution PentraSorb® CRP is a completely new therapeutic, extracorporeal treatment method for the sustained containment of progressive internal tissue damage in patients following acute events such as heart attacks. By filtering the blood plasma outside the body, the so-called C-reactive protein (CRP), which causes tissue damage, is selectively and immediately removed. This gives the medical technology product from Pentracor a unique selling point.
Investment Highlights
PentraSorb® CRP is a pioneering product for the treatment of heart attacks, strokes and other acute conditions. The medical technology product PentraSorb® CRP has a marketing authorisation in the EU and all CE-marked countries without any restrictions for specific clinical pictures, whereas a pharmaceutical solution always requires a specific marketing authorisation for each indication. Except PentraSorb® To date, no drug or other therapy is available worldwide that can selectively lower CRP levels in the body and thus achieve the reduction of infarct and scar sizes after acute heart attacks.
Further information can be found in the bond terms and conditions and the bond factsheet (see Bond).